The use of granulocyte colony stimulating-factor (G-CSF) is safe in patients with limited-stage small-cell lung cancer (SCLC) treated with chemoradiotherapy, according to a post hoc analysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) 2017.
Ensartinib, a small-molecule ALK tyrosine kinase inhibitor (TKI), has demonstrated intracranial response in patients with ALK-positive non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastases.
Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.
Patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of immune-related adverse events (irAEs) after receiving seasonal influenza vaccination, a small study presented at the European Lung Cancer Conference (ELCC) 2017 has shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
Peripheral T cell (PTCL) and natural killer/T cell (NKTCL) non-Hodgkin lymphoma have poor prognoses in elderly adults, though intensive chemotherapy may yield benefit for some, a recent study has found.